Join the Community

Join the Directory

An Open-label, Uncontrolled, Multicenter, Multinational Study on the Efficacy and Safety of Administration of Donor Lymphocytes Depleted of Alloreactive T-cells (ATIR), Through the Use of TH9402 and Light Treatment in an ex Vivo Process, in Patients Receiving a CD34-selected Peripheral Blood Stem Cell Graft From a Related, Haploidentical Donor

Trial Information

An Open-label, Uncontrolled, Multicenter, Multinational Study on the Efficacy and Safety of Administration of Donor Lymphocytes Depleted of Alloreactive T-cells (ATIR), Through the Use of TH9402 and Light Treatment in an ex Vivo Process, in Patients Receiving a CD34-selected Peripheral Blood Stem Cell Graft From a Related, Haploidentical Donor

Allogeneic stem cell transplantation is the treatment of choice for many patients with
leukemia and other hematologic malignancies. However, a major limitation of this therapy is
that for a significant number of patients no fully HLA-matched donor can be found. The
application of partially HLA-matched (haploidentical) family donors, who are virtually
always available, has some complications. If there is no T-cell add-back it increases the
risk for life-threatening infections and disease relapse, while in case of T-cell add-back
the risk for graft-versus-host disease is raised.

Kiadis Pharma has developed a method to selectively deplete host alloreactive T-cells
through photodynamic therapy, using TH9402 ex vivo. The donor lymphocyte preparation
depleted of functional host alloreactive T-cells (ATIR) is administered to the patient 28-42
days after the stem cell transplant.

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.